Director/PDMR Shareholding
15 May 2024 15:00 BST
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 13 May 2024, Pascal Soriot, Chief Executive Officer, was granted an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
This award forms part of the AZPSP award granted to Mr Soriot on 4 March 2024. As described in AstraZeneca's 2023 Directors' Remuneration Report, it has been made in accordance with the Directors' Remuneration Policy and amended rules of the AZPSP approved by shareholders at the Company's 2024 Annual General Meeting.
| PDMR | Ordinary Shares granted under the AZPSP | Award price per Ordinary Share |
| Pascal Soriot | 29,474 | £100.81 |
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance. The performance measures will be assessed over a three-year performance period (1 January 2024 to 31 December 2026). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2023, which is available on the Company's website at www.astrazeneca.com/annualreport2023.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Pascal Soriot | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292 | ||||
| b) | Nature of the transaction | Grants of share awards under the AstraZeneca Performance Share Plan | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information- Aggregated volume- Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 13 May 2024 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.